These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 7072727)

  • 41. FDA's Rx for better medication information.
    Farley D
    FDA Consum; 1995 Nov; 29(9):5-10. PubMed ID: 10152787
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Guidance of FDA's expectations of medical device manufacturers concerning the year 2000 date problem--FDA. Notice.
    Fed Regist; 1998 Jun; 63(121):34433-42. PubMed ID: 10180297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDA commissioner discusses issues of concern to hospital pharmacists. Interview by William A. Zellmer.
    Goyan JE
    Am J Hosp Pharm; 1980 May; 37(5):738-40 contd. PubMed ID: 7386484
    [No Abstract]   [Full Text] [Related]  

  • 44. Unapproved uses of approved drugs: The physician, the package insert, and the FDA.
    Pediatrics; 1978 Aug; 62(2):262-4. PubMed ID: 693165
    [No Abstract]   [Full Text] [Related]  

  • 45. The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health.
    Spencer HM
    Am Univ Law Rev; 2002 Jun; 51(5):999-1050. PubMed ID: 12197546
    [No Abstract]   [Full Text] [Related]  

  • 46. FDA proposes patient package inserts for most drugs.
    Mayberger HW; Bell BJ
    Leg Aspects Med Pract; 1979 Oct; 7(10):42-4. PubMed ID: 263192
    [No Abstract]   [Full Text] [Related]  

  • 47. Quality mammography standards. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
    Fed Regist; 1999 Jun; 64(116):32404-7. PubMed ID: 10558582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Procedures for emergency or treatment use of investigational drugs.
    Klecker RJ; Cipolle RJ
    Am J Hosp Pharm; 1987 May; 44(5):1086-9. PubMed ID: 3605118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comprehensive program for handling hazardous drugs.
    Arrington DM; McDiarmid MA
    Am J Hosp Pharm; 1993 Jun; 50(6):1170-4. PubMed ID: 8517456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sounding board. Creative tension: FDA and medicine.
    Kennedy D
    N Engl J Med; 1978 Apr; 298(15):846-50. PubMed ID: 345121
    [No Abstract]   [Full Text] [Related]  

  • 51. Hospital pharmacies watch prescriptions as debate rages over 'off-label' drug use.
    Wagner M
    Mod Healthc; 1992 May; 22(19):62. PubMed ID: 10117635
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(90):31123-5. PubMed ID: 12001971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The US Food and Drug Administration and probiotics: regulatory categorization.
    Degnan FH
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is it possible for FDA regulatory scientists and industry scientists to work together?
    Woosley RL
    Clin Pharmacol Ther; 2012 Mar; 91(3):390-2. PubMed ID: 22343817
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient package inserts and the pharmacist's responsibility.
    Fink JL
    Am J Hosp Pharm; 1979 Feb; 36(2):226-9. PubMed ID: 420215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
    Zineh I; Pacanowski MA
    Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The drug approval process and the information it provides.
    Myers A; Moore SR
    Drug Intell Clin Pharm; 1987 Oct; 21(10):821-6. PubMed ID: 3322757
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Legal implications of preparing and dispensing approved drugs for unlabeled indications.
    Podell LB
    Am J Hosp Pharm; 1983 Jan; 40(1):111-3. PubMed ID: 6823981
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.